Why iSpecimen Shares Are Gaining Today?
iSpecimen Inc (NASDAQ:ISPC) has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research.…
Gap’s Athleta Plans Two New Outlet Stores
Gap Inc (NYSE:GPS) said its performance lifestyle brand, Athleta, will launch two outlet stores to its fleet in 2022. Athleta’s new…
Meridian Bioscience To Be Acquired By SD Biosensor, SJL Partners – Read For How Much
SD Biosensor Inc (SDB) and SJL Partners LLC have agreed to acquire Meridian Bioscience Inc (NASDAQ:VIVO) in an all-cash transaction valued…
Galmed’s Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced results showing significant effects of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model. Treatment…
The Daily Biotech Pulse: Merck’s Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours:
BoJo Lost His Mojo: What Drove Boris Johnson’s Fall From Power As UK Prime Minister?
What a difference a day makes. Following yesterday’s bellicose pronouncement before the U.K.
Dogness Announces Retail Distribution Partnership With Xiuhu
Dogness Continues to Build Momentum in its Largest Revenue Markets
DONGGUAN, China, July 7, 2022 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company")
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
Verve Therapeutics Inc (NASDAQ:VERV) entered into an Amended and Restated Collaboration and License Agreement with Beam Therapeutics Inc (NASDAQ:BEAM), which amended…
Kiromic BioPharma Announces Completion Of Expanded cGMP Manufacturing Facility To Support Cell Therapy Oncology Pipeline
Construction Completion is One of the Pre-requisites to Beginning the Deltacel™ Clinical Trial Activation Later This Year and Addresses a Key Clinical Hold Citation
Kiromic BioPharma, Inc. (NASDAQ:KRBP)
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
Adverum Biotechnologies Inc (NASDAQ:ADVM) announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinical development of…